J&J vs Eli Lilly Pharma Powerhouse Showdown | Business and Finance News

Johnson & Johnson and Eli Lilly are two pharmaceutical titans with wildly different strategies—and fortunes. J&J, a diversified giant with cash-flow king Darzalex and a planned orthopedics spinoff, boasts a healthy balance sheet and steady revenue, even as it navigates drug pricing pressures and lawsuits. Meanwhile, Eli Lilly is exploding—driven by blockbuster weight-loss and diabetes drugs like Mounjaro and Zepbound, which fueled a 45% revenue surge to $65 billion and $20 billion in net income. Though burdened by higher debt and reliance on a few products, Lilly’s pipeline and new low-cost pill options could push revenue to $85 billion next year. Both face regulatory and legal headwinds, but Lilly’s growth is unstoppable—and J&J’s diversified engine remains quietly powerful. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c5d1d911d43d39ca